Associated Papers
Impact of CYP19A1 genetic variations on polycystic ovary syndrome: findings from a case-control study.
Chaudhary H et al.
F&s Science, 2025
The pharmacogenomic landscape in the Chinese: An analytics of pharmacogenetic variants in 206,640 individuals.
Wang LY et al.
Innovation (cambridge (mass.)), 2025
Effect of donor GSTM3 rs7483 genetic variant on tacrolimus elimination in the early period after liver transplantation.
Zhang T et al.
Peerj, 2024
CYP19A1 TC/CC Polymorphism, along with Deletion of GSTM1 and GSTT1 Genes, Strongly Influences Female Infertility Risk.
Casteleiro Alves MM et al.
Antioxidants (basel, Switzerland), 2023
Rare genetic variability in human drug target genes modulates drug response and can guide precision medicine.
Zhou Y et al.
Science Advances, 2021
Association of the CYP17 and CYP19 gene polymorphisms in women with polycystic ovary syndrome from Punjab, Pakistan.
Munawar Lone N et al.
Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology, 2021
Gene variants associated with acne vulgaris presentation and severity: a systematic review and meta-analysis.
Heng AHS et al.
Bmc Medical Genomics, 2021
Genetic polymorphisms associated with polycystic ovary syndrome among Iranian women.
Jamshidi M et al.
International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics, 2021
In silico analysis of nsSNPs in CYP19A1 gene affecting breast cancer associated aromatase enzyme.
Pavithran H et al.
Journal of Genetics, 2021
What does acne genetics teach us about disease pathogenesis?
Common JEA et al.
The British Journal of Dermatology, 2019
Adenomyosis: genetics of estrogen metabolism.
Artymuk N et al.
Hormone Molecular Biology and Clinical Investigation, 2019
The CYP17 MSP AI (T-34C) and CYP19A1 (Trp39Arg) variants in polycystic ovary syndrome: A case-control study.
Rahimi Z et al.
International Journal of Reproductive Biomedicine, 2019
CYP19A1 polymorphisms associated with coronary artery disease and circulating sex hormone levels in a Chinese population.
Meng Y et al.
Oncotarget, 2017
Identifying pathogenicity of human variants via paralog-based yeast complementation.
Yang F et al.
Plos Genetics, 2017
Role of cytochrome P450 genes in breast cancer etiology and treatment: effects on estrogen biosynthesis, metabolism, and response to endocrine therapy.
Blackburn HL et al.
Cancer Causes & Control : Ccc, 2015
Genetic polymorphisms in estrogen-related genes and the risk of breast cancer among Han Chinese women.
Sun MY et al.
International Journal of Molecular Sciences, 2015
Genetic variation in estrogen and progesterone pathway genes and breast cancer risk: an exploration of tumor subtype-specific effects.
Nyante SJ et al.
Cancer Causes & Control : Ccc, 2015
Targeted Resequencing of 30 Genes Improves the Detection of Deleterious Mutations in South Indian Women with Breast and/or Ovarian Cancers.
Rajkumar T et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2015
Association of CYP19 polymorphisms with breast cancer risk: A case-control study.
Surekha D et al.
Journal of Natural Science, Biology, and Medicine, 2014
Analysis of the rs10046 polymorphism of aromatase (CYP19) in premenopausal onset of human breast cancer.
Zins K et al.
International Journal of Molecular Sciences, 2014
A study on genetic variants of Fibroblast growth factor receptor 2 (FGFR2) and the risk of breast cancer from North India.
Siddiqui S et al.
Plos One, 2014
Potentially functional SNPs (pfSNPs) as novel genomic predictors of 5-FU response in metastatic colorectal cancer patients.
Wang J et al.
Plos One, 2014
Positive association of polymorphisms in estrogen biosynthesis gene, CYP19A1, and metabolism, GST, in breast cancer susceptibility.
Ramalhinho AC et al.
Dna and Cell Biology, 2012
Functional analyses of endometriosis-related polymorphisms in the estrogen synthesis and metabolism-related genes.
Wang HS et al.
Plos One, 2012
A non-synonymous coding change in the CYP19A1 gene Arg264Cys (rs700519) does not affect circulating estradiol, bone structure or fracture.
Wang JZ et al.
Bmc Medical Genetics, 2011
[Construction of eukaryotic expression plasmids containing green fluorescent protein gene and CYP19 WT or its variants].
Shao XY et al.
Zhejiang Da Xue Xue Bao. Yi Xue Ban = Journal of Zhejiang University. Medical Sciences, 2011
Lack of association between CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis of 22,090 cases and 28,498 controls.
Mao C et al.
Breast Cancer Research and Treatment, 2010
Identification of CYP19A1 single-nucleotide polymorphisms and their haplotype distributions in a Korean population.
Lee SJ et al.
Journal of Human Genetics, 2010
A bioinformatics approach for the phenotype prediction of nonsynonymous single nucleotide polymorphisms in human cytochromes P450.
Wang LL et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2009
Genetic variation in CYP19A1 and risk of breast cancer and fibrocystic breast conditions among women in Shanghai, China.
Chen C et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 2008
Lack of association between the functional polymorphisms in the estrogen-metabolizing genes and risk for hepatocellular carcinoma.
Yuan X et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 2008
Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients.
Fasching PA et al.
Breast Cancer Research and Treatment, 2008
Possible difference in frequencies of genetic polymorphisms of estrogen receptor alpha, estrogen metabolism and P53 genes between estrogen receptor-positive and -negative breast cancers.
Hamaguchi M et al.
Japanese Journal of Clinical Oncology, 2008
Pharmacogenomics of endocrine therapy in breast cancer.
Weinshilboum R
Advances in Experimental Medicine and Biology, 2008
Polymorphisms in the CYP19A1 (aromatase) gene and endometrial cancer risk in Chinese women.
Tao MH et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 2007
A comprehensive examination of CYP19 variation and risk of breast cancer using two haplotype-tagging approaches.
Olson JE et al.
Breast Cancer Research and Treatment, 2007
Polymorphisms and haplotypes of the gene encoding the estrogen-metabolizing CYP19 gene in Korean women: no association with advanced-stage endometriosis.
Hur SE et al.
Journal of Human Genetics, 2007
CYP19 haplotypes increase risk for Alzheimer's disease.
Huang R et al.
Journal of Medical Genetics, 2006
Multilocus genotypes spanning estrogen metabolism associated with breast cancer and fibroadenoma.
Corder EH et al.
Rejuvenation Research, 2006
Human aromatase: gene resequencing and functional genomics.
Ma CX et al.
Cancer Research, 2005
CYP19 (aromatase) haplotypes and endometrial cancer risk.
Paynter RA et al.
International Journal of Cancer, 2005
Screening for deleterious nonsynonymous single-nucleotide polymorphisms in genes involved in steroid hormone metabolism and response.
Johnson MM et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 2005
Estrogen-metabolizing gene polymorphisms in the assessment of breast carcinoma risk and fibroadenoma risk in Caucasian women.
Hefler LA et al.
Cancer, 2004
A comprehensive haplotype analysis of CYP19 and breast cancer risk: the Multiethnic Cohort.
Haiman CA et al.
Human Molecular Genetics, 2003
Aromatase and breast cancer: W39R, an inactive protein.
Nativelle-Serpentini C et al.
European Journal of Endocrinology, 2002
CYP17 (T34C), CYP19 (Trp39Arg), and FGFR2 (C906T) polymorphisms and the risk of breast cancer in south Indian women.
Samson M et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 0
CYP17 (T-34C) and CYP19 (Trp39Arg) polymorphisms and their cooperative effects on breast cancer susceptibility.
Tüzüner BM et al.
In Vivo (athens, Greece), 0